13 October 2014

Designing Safer Medicines: What Works and What Doesn't

Organised by:

SCI’s Fine Chemicals Group

SCI, London, UK

Registration Closed

This event is no longer available for registration.

Synopsis

This meeting aims to provide practical insights into some of the recent improvements in this key area. It follows on from the success of the 'Designing Safer Medicines' meeting in 2011.
There is a clear need in drug development to reduce attrition from clinical studies especially due to toxicology. It was estimated that a 5-10% improvement in the attrition rate could double the output of marketed drugs and various preclinical approaches and strategies have been developed to help the chemist design safer medicines.

Attendees

This meeting is targeted at all those who are involved in the lead identification and lead optimisation processes in Drug Discovery and those interested in furthering their knowledge of current and emerging approaches to designing better toxicology models and safer Drug Candidates.

Programme

Day 1

09:30: Registration and refreshments
09:55: Welcome and introduction
10:00: Reducing cardiovascular safety-related attrition: the good, the bad, the ugly and the future
Dr Chris Pollard, AstraZeneca
10:40: Screening strategies for Drug-Induced Liver Injury
Dr James Sidaway, Independant
11:20: In vivo models in safety and toxicity: cross-company data sharing to assess what works and what doesn't
Dr Kathryn Chapman, NC3Rs
12:00: Lunch and exhibition
13:30: Investigative approaches to address toxicological issues in drug discovery and development: case examples
Dr Monicah Otieno, Bristol-Myers Squibb
14:10: Designing in safer chemistry space; the use of multiparametric models in predicting drug safety
Dr Nigel Greene, Pfizer Worldwide Medicinal Chemistry
14:50: Early safety evaluation: combining polypharmacology predictions and network biology to prioritize experimental testing
Dr Cedric Merlot, LeadOp Computing
15:15: Refreshments
15:45: Big data analysis - application for designing safer drugs
Dr Edward J Griffen, MedChemica Ltd
16:10: Improving toxicity predictions to design safer acidic molecules
Dr Nigel Swain, Pfizer Worldwide Medicinal Chemistry
16:35: Influence of early safety science in drug discovery
Dr Mark Anderton, AstraZeneca
17:00: Closing remarks
17:10: Wine reception

Venue and Contact

SCI

14/15 Belgrave Square
London SW1X 8PS

Conference Team

Tel: +44 (0)20 7598 1561

Email: conferences@soci.org

Fees

Early Bird Rate - before 29 August 2014

One-Day Fee		Two-Day Fee*
SCI Member	GB£100	SCI Member	GB£175
SCI Student Member	GB£35	SCI Student Member	GB£60
Non-Member	GB£130	Non-Member	GB£235

Standard Rate - after 29 August 2014

One-Day Fee		Two-Day Fee*
SCI Member	GB£115	SCI Member	GB£205
SCI Student Member	GB£40	SCI Student Member	GB£70
Non-Member	GB£150	Non-Member	GB£270

Become an SCI Member and save on this and future events

See Membership Options

Booking Process/Deadlines

For booking terms and conditions click here.

CPD Info

SCI Members attending this meeting are able to claim CPD points.

Exhibitors

Additional Info

Further Information and Sponsorship Opportunities

Discounts are available for dual registration with the 'Highlights in Medicinal Chemistry' meeting which will be run back-to-back with this meeting.
For further information about sponsorship opportunities, please contact the conference team using the details provided below.